Good morning and welcome to the Aquestive Therapeutics Third Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. As a reminder, this call will be recorded. I would now like to introduce your host for today's conference call, Bennett Watson of ICR Westwicke, Investor Relations. You may begin.

Thank you, operator. Good morning and welcome to today's call. On today's call, I am joined by Dan Barber, Chief Executive Officer and Ernie Toth, Chief Financial Officer, who are going to provide an overview of recent business developments and performance for the third quarter 2023, followed by a Q&A session. During the Q&A session, the team will be joined by Dr. Carl Kraus, Chief Medical Officer; Ken Marshall, Chief Commercial Officer and Dr. Steve Wargacki, Senior Vice President Research and Development. As a reminder, the company's remarks today correspond with the earnings release that was issued after market close yesterday. In addition, a recording of today's call will be made available on Aquestive's website within the Investors section shortly following the conclusion of this call. To remind you, the Aquestive team will be discussing some non-GAAP financial measures this morning as part of its review of third quarter 2023 results. A description of these measures, along with a reconciliation to GAAP, can be found in the earnings release issued yesterday, which is posted on the Investors section of Aquestive's website. During the call, the company will be making forward-looking statements. We remind you of the company's Safe Harbor language as outlined in yesterday's earnings release, as well as the risks and uncertainties affecting the company as described in the Risk Factors section and in other sections included in the Company’s annual report on Form 10-K filed with the Securities and Exchange Commission on March 31st, 2023 and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with the SEC. As with any pharmaceutical company, with product candidates under development and products being commercialized, there are significant risks and uncertainties with respect to the company's business and the development, regulatory approval and commercialization of its products and other matters related to operations. Given these uncertainties you should not place undue reliance on these forward-looking statements which speak only as of the date made. Actual results may differ materially from these statements. All forward-looking statements attributable to Aquestive or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement and the cautionary statements contained in the earnings release issued yesterday. The company assumes no obligation to update its forward-looking statements after the date of this conference call, whether as a result of new information, future events or otherwise, except as required under applicable law. With that, I will now turn the line over to Dan.

Thank you, Bennett. I'm pleased to say that we have been able to accelerate the transformation of Aquestive over the last few months. We achieved important milestones across the clinical, regulatory and financial parts of the business since our last earnings call. Let me start with our most recent news. We were excited to refinance our debt last week and pleased with how our new lender, a large leading institutional investor, has worked with us to maintain flexibility in our business. The $45 million facility provides for interest-only payments into mid-2026, well past our upcoming important clinical and regulatory milestones. Importantly, this agreement contains no revenue, EBITDA, or cash covenants, includes zero warrants and allows us the flexibility to launch or partner both Anaphylm and Libervant as we deem appropriate if approved by the FDA. And despite the Fed funds rate having increased by over 120% since our last financing in 2019, our interest rate remains fixed and increased by only one percentage point from the prior debt deal. We are truly pleased with this outcome. This brings me to another important financial point. This past quarter marked the second quarter in a row during which our non-GAAP adjusted EBITDA remained positive after removing our adjusted R&D costs. Simply put, if we weren't investing in the clinical development of Anaphylm Epinephrine Sublingual Film, our business would have a positive non-GAAP adjusted EBITDA through the first nine months of 2023. This, along with our continued strong revenue guidance, positions us well as we start to focus on 2024. In fact, our revenue guidance for 2023 has increased by over 25% from our original guidance provided earlier in the year. Ernie will talk more about our results in a few minutes. Now, let me turn to our pipeline. Investing in the clinical development of Anaphylm remains the top priority. We continue to believe Anaphylm has the potential to transform the company and believe this transformation could happen in 2024. As we reported in October, we were pleased with the FDA's feedback on the design for our pivotal Phase three program. We are reaffirming our guidance that we will start the Phase three pivotal study this quarter and expect to provide top-line data in the first quarter of 2024. Completing our Phase three pivotal study will represent a major clinical milestone for the company. We also continue to believe that patient demand for an oral epinephrine product for the treatment of severe allergic reactions, including anaphylaxis, remains high. Now with nasal sprays delayed, we believe the benefits of an orally administered epinephrine rescue medication are more apparent than ever. Literature and survey data clearly show that many patients fail to carry their epinephrine rescue medical device. And even when they have it with them, patients fail to use their device. Our survey data suggests that patients often take an oral antihistamine pill such as Benadryl before using their rescue medical device. We believe Anaphylm, which has the only oral rescue product under development for anaphylaxis, has the potential to replace the incorrect use of antihistamines and thereby speed up time to symptom abatement. One thing allergists universally agree on is that early use of epinephrine is critical to treating anaphylaxis. Beyond the potentially significant carry-and-use benefits of Anaphylm, the pharmacodynamic clinical data from our recent studies provides the blueprint for a compelling improvement. According to medical experts, during anaphylaxis, the release of histamines causes blood vessels to expand, thereby rapidly dropping an individual's mean arterial pressure or MAP. Maintaining MAP supports the necessary pressure for vital organs, such as the brain and heart, to function normally and reduces the risk of anaphylaxis-related outcomes such as loss of consciousness. In our studies, Anaphylm has been shown to preserve MAP in contrast to auto injectors that have not done so. We are excited about the potential implications for patients. And our medical team will spend more time talking about this data as we move into 2024. To sum up, we believe the projected timeline to FDA approval and market entry compared to the variety of nasal sprays under development is now much tighter than it was. The potential carry-and-use benefits remain significant, and our mean arterial pressure or MAP data continues to be compelling when compared to auto injectors. Now turning to Libervant, we continue to progress towards our April 2024 FDA target action date for our NDA for patients between two and five years old. At this time, there are no open inquiries with the FDA regarding our NDA for this patient group. And we have no reason to believe the FDA won't meet the action date. Market data shows a 31% increase in prescriptions in the two-to-five-year-old space during the third quarter 2023 when compared to the third quarter of 2022. Well over 90% of these scripts were for diazepam rectal gel, the only FDA-approved drug for this age group. We continue to believe the need for an oral product in this space is significant and look forward to working with the FDA to bring Libervant to these patients as soon as possible. We must remind you that in addition to the usual approval risks, we cannot guarantee that even with approval, the FDA will allow Libervant access to the US market. We also continue to believe that based on past behaviors, competitors may actively seek to block the use of Libervant despite its potential benefits to this critical patient population. Now let's turn to our epinephrine prodrug platform. I'm pleased today to talk about advancements in our epinephrine prodrug platform, which we have branded as ADRENAVERSE. We have completed the initial formulation of a topical product using the ADRENAVERSE platform and plan on testing this formulation in humans in the coming months. Based on pre-clinical data we have seen rapid absorption of epinephrine across porcine tissue. As you know, epinephrine is a vasoconstrictor and does not penetrate well through the skin. However, our ADRENAVERSE platform may allow for absorption thereby creating the potential use of this product for a variety of dermatological conditions. The unmet need and prevalence in some of these conditions is significant. We look forward to sharing our findings as we progress this initiative. Our business development activities remain ongoing. Our Libervant and Anaphylm discussions continue in regions around the world. We also continue to believe that as we meet our expected clinical and regulatory milestones, we will be able to generate significant funding from business development transactions. Our base business remains strong. We anticipate continued growth and remain focused on expanding our business capabilities in 2024. In summary, the third quarter was yet another crucial quarter for the company. We refinanced our debt, raised our revenue guidance, and narrowed non-GAAP adjusted EBITDA guidance for 2023. We progressed our Anaphylm program and continue to plan for a Q4 start to our pivotal study. We progressed our Libervant two-to-five-year-old application and remain on track. We completed our initial topical formulations of our ADRENAVERSE platform, and we continue to see growth in our base business. With that, I will turn the call over to Ernie.

Thank you, Dan and good morning everyone. By now, you have seen our financial results in our earnings release that was issued last evening. As we typically do, we will address most of the discussion related to the third-quarter 2023 results in the Q&A. During the third quarter, we continued to execute on our financial strategy to strengthen our financial position by refinancing our outstanding debt as well as managing expenses to extend our cash runway to support the continued development of our lead product, Anaphylm, the first and only non-device based orally delivered epinephrine product. We recently announced the refinancing of our outstanding obligations under the 12.5% senior secured notes having a maturity date of June 30th, 2025. The new financing of $45 million by a large leading institutional investor will be used to repay all outstanding obligations under the prior credit facility and for general corporate purposes. The notes are senior secured obligations of Aquestive and will mature on November 1st, 2028. The notes bear interest at a fixed rate of 13.5% per year payable quarterly. Principal will be repaid starting on June 30th, 2026. Importantly, the notes contain no revenue or cash covenants and no warrants for purchase of the company's common stock were issued under the terms of the transaction. The structure of this non-dilutive refinancing transaction maximizes our flexibility in the short-term and reduces our cash requirements by approximately $28 million through June 30, 2025, the due date of the original credit facility. Despite very difficult market conditions, the investors' willingness to invest in our future represents an important step forward in the continued growth of Aquestive. Now let's turn to the recap of our quarterly and year-to-date financial results. Excluding the impact of prior year proprietary sales of Sympazan, total revenues increased from $9.2 million in the third quarter of 2022 to $13 million in the third quarter of 2023. This 42% increase in revenue was primarily driven by higher revenue from the company's five out-licensed products. Total reported revenues were $13 million in the third quarter 2023 compared to $11.5 million in the third quarter 2022. For the third quarter 2023, compared to the prior period, we saw a 193% increase in license and royalty revenue, primarily due to Sympazan and Azstarys, a 36% increase in manufacture and supply revenue from Suboxone and Sympazan, and a 24% increase in co-development and research fees. Excluding the impact of prior year proprietary sales of Sympazan, total revenues increased from $29.9 million for the nine months ended September 30, 2022, to $37.4 million for the nine months ended September 30, 2023, an increase of 25%. Total reported revenues were $37.4 million for the nine months ended September 30, 2023, compared to $37 million for the nine months ended September 30, 2022. The increase was primarily due to increases in manufacture and supply revenue and license and royalty revenue offset by the absence of proprietary product sales subsequent to the out-licensing agreement with Assertio in October 2022. Net loss for the third quarter 2023 was $2 million or $0.03 loss per share. The net loss for the third quarter 2022 was $12.5 million or $0.23 loss per share. The change in net loss was primarily driven by increases in revenues, as previously described, decreases in selling general and administrative expense, including severance costs, and lower administrative costs in our commercial organization subsequent to the out-licensing of Sympazan in October 2022, a decrease in non-cash interest expense, and a decrease in research and development costs and expenses. Our net income for the nine months ended September 30, 2023, was $0.2 million. The net loss for the nine months ended September 30, 2022, was $42.1 million or $0.90 loss per share. Non-GAAP adjusted EBITDA loss was $1.3 million in the third quarter 2023 compared to a non-GAAP adjusted EBITDA loss of $7.7 million in the third quarter of 2022. Non-GAAP adjusted EBITDA income, excluding our continued investment in research and development, was $1.7 million for the third quarter of 2023 compared to a non-GAAP adjusted EBITDA loss, excluding adjusted R&D expenses of $4.6 million in the third quarter of 2022. Cash and cash equivalents were $24.9 million as of September 30, 2023. Under the at-the-market or ATM facility, we accessed $0.2 million during the third quarter of 2023 and $5.3 million during the nine months ended September 30, 2023. The ATM facility has approximately $27.8 million available at September 30, 2023. In addition, during the nine months ended September 30, 2023, approximately 8.7 million common stock warrants were exercised with proceeds of approximately $8.3 million. We continue to be focused in 2023 on the advancement of our epinephrine program and commencing our pivotal PK clinical trial in the fourth quarter. Suboxone currently continues to retain a strong presence in both the US commercial and CMS markets and continues to provide a growth opportunity outside the US. We anticipate additional revenue from our licensed products during the remainder of 2023. Moreover, we will continue to focus on capital conservation to extend our cash runway as far as possible. As outlined in the press release issued last night after market close, based on our third-quarter results and positive outlook for the remainder of 2023, we have revised our full-year 2023 financial guidance as follows. Total revenues increased to approximately $47 million to $50 million from $44 million to $48 million. And non-GAAP adjusted EBITDA loss narrowed to approximately $14 million to $17 million from $19 million to $22 million. Please note our revenue guidance for 2023 no longer includes proprietary net sales for Sympazan, due to the out-licensing agreement with Assertio, but does include manufacture and supply revenue and royalty fees. In addition, our guidance for 2023 includes continued focused R&D investments related to the continued development of Anaphylm, the first and only non-device based orally delivered epinephrine product. With that, I will now turn the line back to the operator to open the line for questions.

Our first question comes from Jason Butler with JMP Securities. Your line is open.

Hi, thanks for taking my questions and congrats on all the progress, especially the debt refinancing. A couple on Anaphylm. Can you maybe just outline for us at a high level the differences in design between the two PK pivotal trials? And then do you plan on conducting these sequentially or when will you initiate the second PK pivotal study? Thanks.

Good morning, Jason. Good to hear your voice. So, and thank you for the congrats on the refinancing. Obviously, we're pleased as well. Anaphylm, I think a good place to start, let me give you a couple of my thoughts and then I will pass it over to Carl Kraus, our Chief Medical Officer, who can walk you through how he thinks about it from a design perspective. But a lot of how we are approaching the final set of studies we need to do here really comes from what we've learned in the marketplace and from the FDA directly, right? So we heard what our competitors, the nasal sprays, have put in the public domain. We've obviously been interacting with the FDA. And the one common theme that we really have been able to see is the FDA has been very consistent. They're very consistent in what they're looking for and what they want to see in order to allow a product in the market and that gives us a lot of confidence in our approach. And quite frankly what they want to see is enough data to get them comfortable that patients in all settings can use the product and have an effective dose that is rapidly administered, right? So obviously, with the nasal sprays, they're dealing with the congestion issue. For us, we outlined previously in our end of Phase 2 study of the things the FDA is focused on with us. So that's what's led us to on the set of studies that we're about to perform. And I will turn it over to Carl, who can walk you through how he's thinking about the design of the studies.

Good morning, Jason. Thank you for the question. So the studies that were detailed really were revolving around first the adult Pivotal and then subsequently the pediatric. The adult, pivotal, we've already reviewed with the agency. They have provided us agreement on all the key elements of that study. And we've only included now some additional elements that will result in some data that will address sustainability. Questions regarding repeat doses, so that will be included. And that will begin as planned in Q4 of this year and data readout in Q1 of next year. And then the subsequent study the pediatric, we'll have to secure alignment on the design, but it should be in accord with a standard pediatric study for the 30 kilogram and above pediatric population. So no real surprises just working on making sure that we have the protocol tidied up and provided to the agency for agreement.

Great. And then just real quick on the prodrug platform, can you just speak to the predictive value of the porcine data? When you think about applications in human clinical studies, is this a model that's been validated in the past?

So Jason in a second I will pass it over to Steve Wargacki, our Head of R&D, who I know you know. But keep in mind we have been working with different animal models especially the mini pig model for I don't know 15 years. So this is a model we know well, but Steve, if you could give your thoughts.

Yeah. I would be happy too. The mini pig model is a well-known established model for sublingual delivery, particularly in anatomy and physiology of the sublingual mucosa where absorption occurs has the same structure thickness and features or the closest structure and features to the human. And thus, that is the model that we've been using for a very long time. And we find it to be very informative.

Great. Thanks for taking the questions.

One moment for our next question. Our next question comes from the line of François Brisebois with Oppenheimer. Your line is open.

Hi. Thank you for addressing my questions and congratulations on your progress. My first question pertains to the pivotal studies mentioned in the press release. It refers to comparisons with autoinjectors and also discusses the study design relating to IM injection. I'd like some clarification on whether you are focusing solely on IM or if you are also comparing against several different autoinjectors regarding the pharmacokinetics for the pivotal studies. Thank you.

Thanks, Franç. I will pass it over to Carl to discuss the design. However, it’s important to note as we approach this pivotal study that we are not introducing anything new. We have consistently compared ourselves to both autoinjectors and manual IM throughout our development. This is essentially a larger scale confirmation of our previous work. Carl will elaborate on our bracketing process.

Yeah. I think that's the critical word which is it's not a comparison to one particular agent, but a bracketing target between established reference drug products. So in this instance, it would be the use of the manual injector as well as autoinjectors and demonstration that we are bracketed over a particular time course that partially you see that have been discussed and reviewed at the last advisory committee meeting. And we do have agreement on the endpoints of those. Partially you see the Cmax agreement on the sample size and of course agreement on the bracketing approach. The pivotal nature of this study now of course includes the added element of demonstration of sustainability which was expected for the repeat. But overall, the intent here is to demonstrate that we are expanding the population so that we can demonstrate bracketing between the currently used agents in the marketplace.

Okay, great. Regarding the pediatric versus adult aspects, is the fourth quarter start in the first quarter specifically applicable to the pediatric side? Also, you mentioned three supportive studies in the press release. Can you clarify if these are part of the fourth quarter start in the first-quarter data? Lastly, could you explain the market opportunity differences between the pediatric and adult segments? Thank you.

I’ll have Carl explain the differences in the studies and their timing, and then Ken, could you discuss the commercial opportunity after Carl is finished?

Yes. So regarding timing, the only study we are proceeding with operationally this year is the pivotal study for adults. As mentioned earlier, we will need further discussions with the agency to agree on the trial design for the pediatric study. Additionally, the supportive studies mentioned in a previous press release are potential studies that may be necessary for the full NDA submission, which will be completed in 2024. However, specific timing has not yet been established, and we do not have full agreement or discussions with the agency concerning the specifics of those study designs. Therefore, the only element we are certain will occur is the pivotal study, which will take place in the fourth quarter of this year.

Yes, I'll take that, the second part of that question. And looking at it from a weight-based standpoint rather as will probably be labeled 90% of the market uses the adult dose. So it's this overwhelming majority is in the 0.3%. Usually up to about age five or six, you're using the junior dose, which represents about 10% of the opportunity.

Okay great. Thank you very much.

One moment for our next question. And our next question comes from the line of Andreas Argyrides with Wedbush Securities. Your line is open.

Good morning. This is Caroline on for Andreas, and thank you for taking our questions. We just have a couple. So just curious what the gating factor is to be getting the pivotal PK study in this quarter? And then on the pediatric study when do you plan to start the process of aligning with the FDA on the design? Is it still reasonable to assume that the trial would be complete by the middle of next year? And then I have a follow-up.

There are no gating factors for starting the pivotal PK study in Q4. We are focused on the operational aspects of getting it up and running. Regarding the pediatric study, we have ongoing discussions with the FDA about its final design, so this isn't a new conversation for us. We are confident that, especially as we gather data from the adult study, we will be ready to begin the pediatric study. Conducting a pediatric study is generally more complex than an adult one, but we believe that given the size and scope of this study, it won't be too expensive or lengthy. Therefore, we think our projected timeline is reasonable.

Okay. Great. And then, I have just one additional question on Libervant. In the 12-year-old and older population, can you just provide any additional insight into the work you're doing to remove the exclusivity block and bring this product to market?

Sure. Yes. I would love to give you and the rest of the community a lot of insight into this area, but it is not an area that at this time we can share a lot. So I would think of Libervant this way in terms of how it fits into our company, I do believe Libervant is a potential important catalyst in 2024, consider it kind of the upside wildcard. The two-to-five-year-old application, we feel good about. We think there's a real need in that space and we think it's a sizable enough opportunity to matter. So we are very focused on that at this point, especially with the near-term target action date ahead of us, but we have not lost sight of the 12 and up application as well. And we continue to believe that there are avenues to bringing our application to market ahead of orphan drug exclusivity exploration for the competing products.

Okay great. Thank you, and congrats on all the progress.

Thanks, Caroline.

One moment for our next question. Our next question comes from the line of Thomas Flaten with Lake Street. Your line is open.

Hey, good morning, guys. And I apologize, if I missed this Dan, but with respect to the upcoming studies that are going on, whether they're pivotal or supportive, are the timelines in the October nine press release still valid? Maybe I missed it, but it sounds like some of them were there was only going to be the pivotal study in the fourth quarter. And I know you guys left the fourth quarter, first quarter window in that press release, but I just wanted to confirm that nothing has shifted from those expectations and at least in my mind, we're kind of set.

No. Thank you, Thomas. I'm actually glad you asked that question so we could clarify. Yeah, the timelines that we put in the October press release just a few weeks ago, remain the same. The additional or supportive study that Franc asked about before and Carl will walk you through, just remember these are smaller studies. So a temperature study, a PH study, those are not significant bodies of work that take months and months to complete. So in terms of completing them and where we will complete them throughout the year, we feel comfortable that by the end of next year, we will have gotten through the work that we need to know where we are in the application process.

Great. And then I don't want to beat the deliver it two to five thing too much, but I'm just curious because there isn't an orphan drug exclusivity in that age group or at least it doesn't appear to be. Is there still a dual process review going on one with the review division, and one with the orphan drug folks?

Yes, the process remains the same. So the Cedar Group, the review division within the FDA will complete their review and either give an approval or whatever else they give on the action date as they would with any application. And then at the exact same time, our understanding is, the orphan drug group would give its position on whether the patient population is free from an exclusivity block, or whether they believe deem it to be blocked by exclusivity. So we do expect based on what we know, that both would happen at the same time.

Got it. Understood. Understood. And just a quick one for Ernie and I know there tends to be variability here, but there was a substantial bump in gross margin. Just any comments on sustainability of that? Or should we expect it to be relatively variable going forward?

Hi, Thomas. Nice to hear your voice. So now on the gross margin, we would expect it to trend where it is on a year-to-date basis going forward.

Got it. Appreciate taking the questions. Thank you.

One moment for our next question. Our next question comes from the line of Raghuram Selvaraju with H.C. Wainwright. Your line is open.

Thanks very much for taking my questions. I was just wondering, if it would be possible for you to offer some additional context around the target dermatological indications that you intend to pursue, with the topical formulation that you had mentioned earlier during your prepared remarks?

Yeah. Thanks, Ram. And so I think the best way to approach giving you more information on that front is, there are a variety of indications that we could look at but it really depends on how the absorption process works, as we go through this first study. So I think a good way to educate all our listeners would be Steve, if you could talk a little bit about how you see the absorption process happening and what you think the potential effects of that could be, with our people with our ADRENAVERSE platform.

Certainly. We believe that our project platform enables our molecules to achieve absorption levels that straight epinephrine cannot due to their unique properties, including absorption methods and interactions with the body. We aim to assess the absorption rate, residence time, tolerability, and other factors of the Adrenaverse platform through the skin. This will help us understand its applicability for various indications that we've received signals for, even outside of clinical settings. While it's still to be determined, the initial studies will guide our future direction, and we are eager to share more as the data develops.

So I think, Ram I know in fairness you are looking to hear about what the indications are and what the opportunities are. I think once we have that data as Steve laid out we can really start being more specific in giving you more detail on that front.

Do you have a sense at this juncture as to whether these might include both acute as well as chronic indications?

Yeah, you know, just to reiterate what Steve and Dan mentioned that the target indications would be reflective of what we learn from the ADME and the penetration and dermal residence. So I think it will be premature to determine what indications they benefit from this intervention until we have more data on the preclinical front.

Okay. And then just one quick question clarification on the debt financing. It stated in the press release that the note holders are entitled to a tiered royalty of between 1% and 2% of worldwide net sales of Libervant until the earlier of either the first sale of Anaphylm and eight years from the first sale of Libervant. So I'm assuming that if what you expect, let's call it a best-case scenario unfolds for both Libervant and Anaphylm, this tiered royalty on worldwide net sales of Libervant would not likely persist for very long. Am I thinking about that correctly?

Yeah. No, as soon as there is a sale of an Anaphylm product anywhere on the globe, the Libervant royalty goes away. You have that exactly right.

Thank you.

Thanks, Ram.

One moment for the next question. Our next question comes from James Molloy with Alliance Global Partners. Your line is open.

Hey, guys. Thanks for taking my question. Just a quick question on the remaining trials. What's the all-in cost of the remaining trials? And again presuming things go well in the trials put up the data of the anticipated should what's the expectation for being ready for an NDA filing?

Good morning, Jim. To address your second question, we still anticipate filing by the end of 2024. Based on our previous updates from the August earnings call and the October press release, there has been no change in that timeline. We haven't disclosed the total costs for the remaining studies yet. However, I want to emphasize that these are pharmacokinetic studies involving healthy volunteers, which means they are relatively cost-effective to conduct. Ernie, do you have anything to add?

No, I think what you said considering that we've not given any public guidance on this number, that it's not an expensive study for us to complete and we are well on our way there.

Great. Maybe two quick follow ups. Thank you for that. Any competitive intelligence on competitor ARS Pharma and Neffy refiling their NDA and I guess you guys are you guys still expecting that you guys will the FDA will ask for an Adcom for you guys?

Yeah. So the only competitive intelligence we have on Neffy is exactly what you or other people in the public domain know. We only hear what's in the public domain. So I'll leave it to ARS and the team there to define what that means for them. In terms of an Adcom, I think that is an unknown at this point. We will of course be prepared if that is something the FDA does want. You could argue either way on that one. You could say well the FDA has already done that come in this space. Why would they do another one? Or you could say we're a different dosage form. Maybe they want to spend some time with people in an Adcom setting. Either way, we will be ready.

Great. Thank you for taking the questions.

Thank you, Amy. And thank you for joining us this morning. As you've heard we're very pleased with the Q3 2023 results that we just discussed and we remain excited for the potential that lies ahead for us and for the company. And we look forward to speaking with all of you again soon. Have a good day.

This concludes today's conference call. Thank you for participating. You may now disconnect.